Recently, the de novo pyrimidine synthesis pathway has been recognized as a potential therapeutic target for AML and other diseases caused by rapidly proliferating cells, with a particular focus on dihydroorotate dehydrogenase (DHODH), the rate-limiting enzyme in this pathway (Figure 1) (14, 15). Here, DHODH is linked to acute myeloid leukemia.